Treatment of Helicobacter pylori infection in atrophic gastritis.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
amoxicillin 3 infectiousdiseasesdrugs
clarithromycin 6 infectiousdiseasesdrugs
metronidazole 8 infectiousdiseasesdrugs
tetracycline 4 infectiousdiseasesdrugs

There are not enough annotations found in this document to create the proximity graph.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
amoxicillin 20972 (%)ReferenceCountriesPatients, nTreatment regimenCured patientsSánchez Cuén et al[[55]], 2016Mexico57Omeprazole (40 mg), amoxicillin (1 g), and clarithromycin (500 mg), twice daily for two wk49 (85.9)Vannella et al[[14]], 2011Italy192Dicitrate
amoxicillin 21134 for two wk49 (85.9)Vannella et al[[14]], 2011Italy192Dicitrate bismuthate (120 mg qds) for 4 wk, plus amoxicillin (1 g tds), and metronidazole (250 mg tds) during the first 2 wk136 (70.8)Kamada et al[[56]], 2003Japan45Omeprazole
amoxicillin 21270 metronidazole (250 mg tds) during the first 2 wk136 (70.8)Kamada et al[[56]], 2003Japan45Omeprazole (20 mg), amoxicillin (1500 mg) and clarithromycin (600 mg) for 1 wk35 (82.2)Ohkusa et al[[57]], 2001Japan163Proton-pump inhibitor
clarithromycin 18820 strain, smoking, and low compliance. However, the increasing antibiotic resistance, particularly against clarithromycin , seems to be played a major role in poor outcomes. To limit the problem of resistance, a combination
clarithromycin 20995 regimenCured patientsSánchez Cuén et al[[55]], 2016Mexico57Omeprazole (40 mg), amoxicillin (1 g), and clarithromycin (500 mg), twice daily for two wk49 (85.9)Vannella et al[[14]], 2011Italy192Dicitrate bismuthate (120
clarithromycin 21296 the first 2 wk136 (70.8)Kamada et al[[56]], 2003Japan45Omeprazole (20 mg), amoxicillin (1500 mg) and clarithromycin (600 mg) for 1 wk35 (82.2)Ohkusa et al[[57]], 2001Japan163Proton-pump inhibitor and antibiotic therapy
clarithromycin 22377 efficacy[[60],[61]]. This combination mainly remained a rescue therapy during the following ten years, when the PPI- clarithromycin -based triple therapy was the standard therapy[[62]]. Bismuth has an established history in the treatment
clarithromycin 24268 Pylera® achieved eradication rates ranging between 84% and 97%. Eradication rates were similar for clarithromycin - and metronidazole-resistant strains. Eradication rates with an omeprazole, bismuth, metronidazole and
clarithromycin 24551 metronidazole-resistant and -sensitive strains. This effect was not seen with the use of triple therapy in cases of clarithromycin resistance. Previous clinical trials did not report any serious side effects from bismuth-based regimens,
metronidazole 21161 et al[[14]], 2011Italy192Dicitrate bismuthate (120 mg qds) for 4 wk, plus amoxicillin (1 g tds), and metronidazole (250 mg tds) during the first 2 wk136 (70.8)Kamada et al[[56]], 2003Japan45Omeprazole (20 mg), amoxicillin
metronidazole 21863 the discovery of Hp, Marshall highlighted that some antimicrobial compounds (e.g., bismuth salts and metronidazole ) had been used to treat peptic ulcer disease in the past with some success. These results led to a renewed
metronidazole 23019 promising treatment option, especially in the recent galenic formulation, bismuth subcitrate potassium, metronidazole , and tetracycline (BMT, sold under licence as Pylera®). In particular, this formula consists of 140
metronidazole 23202 particular, this formula consists of 140 mg of bismuth subcitrate potassium (equivalent to Bi2O3), 125 mg of metronidazole and 125 mg of tetracycline hydrochloride given as a three-in-one capsule four times daily for ten days[[63]].
metronidazole 23738 compounds are taken separately. Undeniably, 14 d triple therapy with bismuth salts, tetracycline and metronidazole was the first therapy to achieve consistently high Hp eradication rates[[2],[63]]. The bismuth-based
metronidazole 24288 eradication rates ranging between 84% and 97%. Eradication rates were similar for clarithromycin- and metronidazole -resistant strains. Eradication rates with an omeprazole, bismuth, metronidazole and tetracycline regimen
metronidazole 24368 clarithromycin- and metronidazole-resistant strains. Eradication rates with an omeprazole, bismuth, metronidazole and tetracycline regimen appeared comparable between metronidazole-resistant and -sensitive strains.
metronidazole 24435 rates with an omeprazole, bismuth, metronidazole and tetracycline regimen appeared comparable between metronidazole -resistant and -sensitive strains. This effect was not seen with the use of triple therapy in cases of
tetracycline 23038 option, especially in the recent galenic formulation, bismuth subcitrate potassium, metronidazole, and tetracycline (BMT, sold under licence as Pylera®). In particular, this formula consists of 140 mg of bismuth subcitrate
tetracycline 23230 140 mg of bismuth subcitrate potassium (equivalent to Bi2O3), 125 mg of metronidazole and 125 mg of tetracycline hydrochloride given as a three-in-one capsule four times daily for ten days[[63]]. Generally, this formula
tetracycline 23721 possible when the compounds are taken separately. Undeniably, 14 d triple therapy with bismuth salts, tetracycline and metronidazole was the first therapy to achieve consistently high Hp eradication rates[[2],[63]].
tetracycline 24386 and metronidazole-resistant strains. Eradication rates with an omeprazole, bismuth, metronidazole and tetracycline regimen appeared comparable between metronidazole-resistant and -sensitive strains. This effect was
Select Disease Character Offset Disease Term Instance

You must be authorized to submit a review.